PGNY250117P25000
- 11.10
- 0.000.00%
Progyny Newsroom
Truist Financial Maintains Progyny(PGNY.US) With Hold Rating
Progyny (PGNY) Gets a Hold From Truist Financial
Leerink Partners Maintains Progyny(PGNY.US) With Hold Rating, Cuts Target Price to $20
BofA Securities Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $21
Express News | Progyny Inc : Leerink Partners Raises Target Price to $20 From $17
Express News | Progyny : Now Expect Q4 Revenue, Net Income and Adj Ebitda Slightly Above Ranges Provided in Nov
Express News | Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services
Express News | Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Progyny Pick of the Week at Smart Insider Following CEO, Executive Chair Stock Purchases
Insider Spends US$3.0m Buying More Shares In Progyny
Progyny Up Over 11%, on Pace for Largest Percent Increase Since February 2023 -- Data Talk
Progyny, Inc. (PGNY): A Bull Case Theory
Progyny up 6% on Insider Buys
Progyny(PGNY.US) Officer Buys US$3.03 Million in Common Stock
$Progyny(PGNY.US)$ Officer Anevski Peter purchased 209.5K shares of common stock on Dec 23, 2024 at an average price of $14.4825 for a total value of $3.03 million.Source: Announcement What is
Progyny CEO Peter Anevski Buys $3 Million in Shares
Is Now The Time To Look At Buying Progyny, Inc. (NASDAQ:PGNY)?
Progyny Price Target Cut to $17.00/Share From $22.00 by JP Morgan
J.P. Morgan Downgrades Progyny(PGNY.US) to Hold Rating, Announces Target Price $17
Progyny's Short-Term Challenges and Long-Term Promise: A Hold Rating Amidst Market Pressures
Express News | Progyny Inc : JP Morgan Cuts to Neutral From Overweight